Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear

NCT ID: NCT01765972

Last Updated: 2018-06-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-12-31

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this clinical trial is to evaluate the eye's response to three test soft contact lenses as well as no lens wear, with respect to Corneal Staining.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corneal Swelling

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test 1/Spectacles/Test 2/Test 3

Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.

Group Type OTHER

etafilcon A with Lacreon

Intervention Type DEVICE

contact lens with Lacreon

etafilcon A with Lacreon with print

Intervention Type DEVICE

contact lens with Lacreon and cosmetic print

etafilcon A with print

Intervention Type DEVICE

contact lens with print

Spectacles (habitual)

Intervention Type DEVICE

Spectacles

Test 2/Test 3/ Spectacles/Test 1

Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.

Group Type OTHER

etafilcon A with Lacreon

Intervention Type DEVICE

contact lens with Lacreon

etafilcon A with Lacreon with print

Intervention Type DEVICE

contact lens with Lacreon and cosmetic print

etafilcon A with print

Intervention Type DEVICE

contact lens with print

Spectacles (habitual)

Intervention Type DEVICE

Spectacles

Test 3/Test 1/ Test 2/ Spectacles

Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.

Group Type OTHER

etafilcon A with Lacreon

Intervention Type DEVICE

contact lens with Lacreon

etafilcon A with Lacreon with print

Intervention Type DEVICE

contact lens with Lacreon and cosmetic print

etafilcon A with print

Intervention Type DEVICE

contact lens with print

Spectacles (habitual)

Intervention Type DEVICE

Spectacles

Spectacles/Test 2/Test 1/Test 3

Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.

Group Type OTHER

etafilcon A with Lacreon

Intervention Type DEVICE

contact lens with Lacreon

etafilcon A with Lacreon with print

Intervention Type DEVICE

contact lens with Lacreon and cosmetic print

etafilcon A with print

Intervention Type DEVICE

contact lens with print

Spectacles (habitual)

Intervention Type DEVICE

Spectacles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

etafilcon A with Lacreon

contact lens with Lacreon

Intervention Type DEVICE

etafilcon A with Lacreon with print

contact lens with Lacreon and cosmetic print

Intervention Type DEVICE

etafilcon A with print

contact lens with print

Intervention Type DEVICE

Spectacles (habitual)

Spectacles

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Test 1 Test 2 Test 3

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. The subject must appear able and willing to adhere to the instructions set forth in the clinical protocol.
3. The subject must be between 18 and 45 years of age.
4. The subject must be an adapted soft contact lens wearer in both eyes.
5. The subject must be of East or Southeast Asian descent, e.g. ethnic Chinese, Japanese, Korean, Malay, Vietnamese, Indonesian, Filipino, etc. (it is preferred but not required that both the subject's biological parents are East or Southeast Asian ethnicity, by self report).
6. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D in each eye.
7. The subject's refractive cylinder must be no more than 1.00D in each eye.
8. The subject must have best corrected visual acuity of +0.14 logMAR (equivalent to 20/25-2) or better in each eye.
9. Subjects must own a wearable pair of spectacles and wear them on the day of the initial visit, during the washout before each phase and during the no lens wear phase.
10. The subject must have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion Criteria

1. Are currently pregnant or lactating by self report (subjects who become pregnant during the study will be discontinued).
2. Have any ocular or systemic allergies or diseases that may interfere with contact lens wear.
3. Have any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but may not be limited to, diabetes. hyperthyroidism, recurrent herpes simplex/zoster, Sjogren's syndromes, xerophthalmia, acne rosacea, Stevens-Johnson syndromes, HIV/AIDS, hepatitis, and tuberculosis.
4. Use of any topical medications such aas eye drops or ointments.
5. Have entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosion, or aphakia.
6. Had any previous, or planned ocular or intraocular surgery (e.g. cataract surgery, radial keratotomy, PRK, LASIK, etc.).
7. Have any grade 2.0 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the Efron classification scale or any other ocular abnormality that may contraindicate contact lens wear.
8. Have any known hypersensitivity or allergic reaction to one of the study products.
9. Have any ocular infection.
10. Have any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
11. Have participated in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
12. Have any infectious disease (e.g. hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g. HIV by self report).
13. Currently wear their contact lenses on an extended wear basis.
14. Are an employee of the investigational clinic (e.g. Investigator, Coordinator, Technician)
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Waterloo, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR-5252

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Daily Disposable Comparison Study
NCT02094677 COMPLETED NA